Papillomavirus-like particles for serology and vaccine development

Intervirology

Volumn 39, Issue 1-2, 1996, Pages 54-61

  Kirnbauer, R ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

Author keywords

Carcinogenesis; Neoplasia; Papillomavirus; Serology; Vaccine; Virus like particles

Indexed keywords

CAPSID PROTEIN; EPITOPE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS VACCINE;

ARTICLE; CANCER RISK; CONDYLOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; NONHUMAN; PRIORITY JOURNAL; SEROLOGY; UTERINE CERVIX CANCER; VACCINATION; VIRUS ASSEMBLY; VIRUS CARCINOGENESIS; VIRUS PARTICLE; WART VIRUS;

ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TUMOR VIRUS INFECTIONS; VACCINES, SYNTHETIC; VIRAL VACCINES; VIRION; VIRUS ASSEMBLY; VIRUS LATENCY;

ANIMALIA; EUKARYOTA; HUMAN PAPILLOMAVIRUS TYPES; MIRIDAE; PAPILLOMAVIRUS;

EID: 0029841996     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000150475     Document Type: Article

References (82)

1. zur Hausen H: Viruses in human cancer, Science 1991:254: II67-II73.
2. Syrjänen K, Gissmann L, Koss LG: Papillomaviruses and Human Disease, Berlin Springer, 1987, p 518.
3. de Villiers E-M: Heterogeneity of the human papillomavirus group, J Virol 1989:63:4898-4903.
4. Salzman NP, Howley PM: The Papovaviridac, New York, Plenum Press, vol 2: The Papillomaviruses, p 392.
5. Wemess BA, Munger K, Howley PM: Role of the human papillomavirus oncoproteins in transformation and carcinogenic progression: in DeVita VT, Heilman S, Rosenberg SA (cds): Important Advances in Oncology, Philadelphia Lippincott, 1991, pp 3-18.
6. Kivial NB, Koutsky LA: Specific human papillomavirus types as the causal agents of most cervical intraepithélial neoplasia: Implications for current views and treatment, J Nall Cancer Inst 1993:85:934-935.
7. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ: Human papillomavirus infection of the cervix: Relative risk associations of 15 common anogenital types, Obstet Gynecol 1992;79:328-337.
8. Schiffman M, Bauer HM, Hoover RN, Glass GA, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ, Wacholder S, Stanton CK, Manos MM: Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia, J Natl Cancer Inst 1993:85:958-964.
9. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Pcto J, Schiffman MH, Moreno V, Kurman R, Shah KV: Prevalence of human papillomavirus in cervical cancer: A worldwide perspective, J Natl Cancer Inst 1995:7:796-802.
10. zur Hausen H, Schneider A: The role of papillomaviruses in anogenital cancer, in Salzman NP, Howley PM (eds): The papillomaviruses, New York, Plenum Publishing, 1987, pp 245-263.
11. Maden C, Sherman KJ, Beckmann AM, Hislop TG, Teh CZ, Ashley RL, Daling JR: History of circumcision, medical conditions, and sexual activity and risk of penile cancer, J Natl Cancer Inst 1993:85:19-24.
12. Munoz N, Bosch FX, Shah KV, Meheus A: The epidemiology of cervical cancer and human papillomavirus, IARC Sei Publ 1992;119:3- 56.
13. Boring CC, Squires TS, Tong T: Cancer statistics, 1991, CA 1992:41:19-51.
14. Munoz N, Bosch FX: HPV and cervical cancer: Review of case-control and cohort studies: in Munoz N, Bosch FX, Shah KV, Meheus A (eds): The Epidemiology of Cervical Cancer and Human Papillomavirus, IARC Sei Publ 1992;119:251-260.
15. Parkin DM, Stjcrnsward J, Muir CS: Estimates of the worldwide frequency of twelve major cancers, Bull WHO 1984:62:163-182.
16. Mongella G: Global approaches to the promotion of women’s health, Science 1995:269:789- 790.
17. Hawley-Nclson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT: HPV 16 E6 and E7 proteins cooperate to immortalize primary human foreskin keratinocytcs, EMBO J 1989:8:3905- 3910.
18. Hudson JB, Bedell MA, McCance DJ, Laimin-is LA Immortalization and altered differentiation of human keratinocytcs in vitro by the E6 and E7 open reading frames of human papillomavirus type 18, J Virol 1990:64:519-526.
19. Munger K, Phelps WC, Bubb V, Howley PM, Schlegcl R: The E6 and E7 genes of the human papillomavirus type 16 together are necessary' and sufficient for transformation of primary' human keratinocytes, J Virol 1989:63:4417- 4421.
20. Schneider-Gadicke A, Schwarz E: Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes, EM BO J 1986:5:2285-2292.
21. Smotkin D, Wettstcin FO: Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein, Proc Natl AcadSci USA 1986:83:4680-4684.
22. Scheffncr M, Wemess BA, Huibregtsc JM, Levine AJ, Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes degradation of p53, Cell 1990:63: 1129-1136.
23. Wemess BA, Levine AJ, Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53, Science 1990:248:76-79.
24. Dyson N, Howley PM, Munger K, Harlow E: The human papillomavirus-16 E7 oncoprotein is able to bind the retinoblastoma gene product, Science 1989:243:934-937.
25. Barbosa MS, Edmonds C, Fisher C, Schiller IT, Lowy DR, Vousden KH: The region of the I1PV E7 oncoprotein homologous to adenovirus El a and SV40 large T antigen contains separate domains for Rb bindingand casein kinase 11 phosphorylation, EMBO J 1990;9:153-160.
26. Crook T, Tidy JA, Vousden KH: Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and rra/is-activation, Cell 1991:67:547-556.
27. Munger K, Yce CL, Phelps WC, Pietcnpol JA, Moses H, Howley PM: Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences, J Virol 1991;65:3943-3948.
28. Bauer HM, Greer CE, Chambers JC, Tashiro CJ, Cimera CJ, Reingold J, Manos MM: Genital human papillomavirus infection in female university students as determined by a PCR-based method, JAMA 1991:265.472-477.
29. Koutskv LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, ReRouen TA, Galloway DA, Vemon D, Kiviat NB: A cohort study of the risk of cervical intraepithc-lial neoplasia grade 2 or 3 in relation to papillomavirus infection, N Engl J Med 1992;327: 1272-1278.
30. Koss LG: The Papanicolaou test for cervical cancer detection: A triumph and a tragedy, JAMA 1989:261:737-743.
31. Schneider A, Koutskv LA: Natural history and epidemiologic features of genital HPV infection: in Munoz N, Bosch FX, Shah KV, Mc-heus A (eds): The epidemiology of Cervical Cancer and Human Papillomavirus, 1ARC Sci Publ 1992;119:25-52.
32. Meijer CJLM, van den Brule AJC, Snijders PJF, Helmcrhorst T, Kenemans P, Walboom-ers JMM: Detection of human papillomavirus in cervical scrapes by the polymerase chain reaction in relation to cytology: Possible implications for cervical cancer screening: in Munoz N, Bosch FX, Shah KV, Meheus A (eds): The Epidemiology of Human Papillomavirus and Cervical Cancer, IARC Sci Publ 1992:119: 271-281.
33. Schiffman MH, Kiviat NB, Burk RD, Shah KV, Daniel RW, Lewis R, Kuypers J, Manos MM, Scott DR, Sherman ME, et al: Accuracy and interlaboratory reliability of human papillomavirus DNA testing by hybrid capture, J Clin Microbiol 1995:33:545-550.
34. Schiffman MH: Validation ofhybridization assays: Correlation of filter in situ, dot blot and PCR with Southern blot: in Munoz N, Bosch FX, Shah KV, Meheus A (eds): The Epidemiology of Cervical Cancer and Human Papillomavirus, I ARC Sci Publ 1992:119:169-179.
35. Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ: Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance, Am J Obstct Gynecol 1995:172:946-954.
36. Galloway DA: Serological assays for the detection of HPV antibodies; in Munoz N, Bosch FX, Shah KV, Meheus A (eds): The Epidemiology of Human Papillomavirus and Cervical Cancer, IARCSci Publ 1992:119:147-161.
37. Ghirn S, Christensen ND, Krcidcr JW, Jenson AB: Comparison of neutralization of BPV-I infection of Cl27 cells and bovine fetal skin xenografts, Ini J Cancer 1991;49:285-289.
38. Bonncz W, Rin CD, Rose RC, Reichntan RC: Use of human papillomavirus type 11 virions in an ELISA to detect specific antibodies in humans with condylomata acuminata, J Gen Virol 1991;72:1343-1347.
39. Christensen ND, Krcider JW, Shah KV, Rando RF: Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions, J Gen Virol 1992:73:1261- 1267.
40. Steele JC, Gallimore PH: Humoral assays of human sera to disrupted and nondisrupted epitopes of human papillomavirus type 1, Virology 1990;174:388-398.
41. Kreider JW, Howett MK, Leure-Duprcc AE, Zaino RJ, Weber JA: Laboratory production in vivo of infectious human papillomavirus type 11, J Virol 1987;61:590-593.
42. Bonncz W, Kashima HK, Lcventhal B, Mounts P, Rose RC, Rcichman RC, Shah KV: Antibody response to human papillomavirus (HPV) type 11 in children with juvcnile-onset recurrent respiratory' papillomatosis (RRP), Virology 1992:188:384-387.
43. Kraus SJ, Stone KM: Management of genital infection caused by human papillomavirus, Rev Infect Dis 1990:12:S620-S632.
44. Beutner KR: Human papillomavirus infection, J Am Acad Dermatol 1989:20:114-123.
45. Cason J, Khan SA, Best JM: Towards vaccines against human papillomavirus type 16 genital infections, Vaccine 1993; 11:630-611.
46. Chen L, Thomas EK, Hu SI., Hellstrom I, Hell-strom KE: Human papillomavirus type 16 nu-cleoprotein E7 is a tumor rejection antigen, Proc Natl Acad Sci USA 1991:88:110-114.
47. Mcneguzzi G, Cerni C, Kieny MP, Lathes R: Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia virus expressing E6 and E7, Virology 1991:181: 62-69.
48. Jarrctt WF, Smith KT, O'Neil BW, Gaukrogcr JM, Chandrachud LM, Grindlay GJ, McGar-vie GM, Campo MS: Studies on vaccination against papillomaviruses: Prophylactic and therapeutic vaccination with recombinant structural proteins, Virology 1991:184:33-42.
49. Feltkamp MC, Smits HL, Vierboom MP, Min-naar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melicf CJ, Kast WM: Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformcd cells, EurJ Immunol 1993:23:2242-2249.
50. Pilacinski WP, Glassman DL, Glassntan KF, Reed DE, Lum MA, Marshall RF, Muscoplat CC, Faras AJ: Immunization against bovine papillomavirus infection, Ciba Found Symp 1986:120:136-156.
51. Lin Y-L, Borenstein LA, Selvakumar R, Ahmed R, Wettstcin FO: Effective vaccination against papilloma development by immunization with LI or 1.2 structural protein of cottontail rabbit papillomavirus, Virology 1992:187: 612-619.
52. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT: Papillomavirus LI major capsid protein self-assembles into virus-like particles that are highly immunogenic, Proc Natl Acad Sci USA 1992:89:12180-12184.
53. Rose RC, Bonnez W, Rcichman RC, Garcea RL: Expression of human papillomavirus type 11 LI protein in insect cells: In vivo and in vitro assembly of virus-like particles, J Virol 1993;67:1936-1944.
54. Hagcnsee M, Yaegashi N, Galloway D: Self-assembly of human papillomavirus type I cap-sids by expression of the LI protein alone or by coexpression of the LI and L2 capsid proteins, J Virol 1993;67:315-322.
55. Hofmann K, Cook J, Joyce J, Brown D, Schultz L, George II, Rosolowsky M, Fife K, Jansen K: Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae, Virology 1995:209:506-518.
56. Volpers C, Schirmachcr P, Streeck R, Sapp M: Assembly of the major and minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells, Virology 1994:200:504-512.
57. Sasagawa T, Pushko P, Steers G, Gschmcissner S, Hajibagheri M, Finch J, Crawford L, Tom-ntasino M: Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe, Virology 1995;206:126-135.
58. Hagcnsee M, Olson N, Baker T, Galloway D: Three-dimensional structure of vaccinia virus-produced human papillomavirus type I cap-sids, J Virol 1994:68:4503-4505.
59. Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, Brown JC: Structures of bovine and human papillomaviruses, Biophys J 1991; 60:1445-1456.
60. Xi SZ, Banks LM: Baculovirus expression of the human papillomavirus type 16 capsid proteins: Detection of 1.I-L2 protein complexes, J Gen Virol 1991:72:2981-2988.
61. Kimbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, Lowy DR, Schiller JT: Efficient self-assembly of human papillomavirus type 16 LI and LI plus L2 into virus-like particles, J Virol 1993;67:6929-6936.
62. Zhot J, Sun XY, Slenzel DJ, Frazer IH: Expression of vaccinia recombinant HPV 16 LI and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles, J Virol 1991:185:251-257.
63. Kimbauer R, Hubbcrt NL, Wheeler CM, Becker TB, Lowy DR, Schiller JT: A virus-like particle ELISA detects serum antibodies in a majority of women infected with human papillomavirus type 16, J Natl Cancer Inst 1994;86:494-499.
64. Widerof TL, Schiffman M, Nonnenmacher B, Hubbcrt N, Kimbauer R, Greer C, Lowy D, Lorincz A, Manos M, Glass A, Scott D, Sherman M, Kurman RJ, Buckland J, Tarone R, Schiller J: Evaluation of scrorcactivity to HPV 16 virus-like particles in an incident casc-con-trol study of cervical neoplasia, J Infect Dis 1995:172:1425-1430.
65. Wikström A, van Doornum G, Kimbaucr R, Quint W, Dillner J: Prospective study on the development of antibodies against human papillomavirus type 6 among patients with condy-lomata acuminata or new asymptomatic infection, J Med Virol 1995;46:368-374.
66. Wikström A, van Doornum GJ, Quint WG, Schiller JT, Dillner J: Identification of human papillomavirus scroconversions, J Gen Virol 1995:76:529-539.
67. Rose RC, Bonncz W, Da Rin C, McCancc DJ, Reichman RC: Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles, J Gen Virol 1994;75:2445-2449.
68. LeCann P, Coursaget P, lochmann S, Touze A: Self-assembly of human papillomavirus type 16 capsids by expression of the LI protein in insect cells, FEMS Microbiol Lett 1994:117: 269-274.
69. Christensen ND, Kreider JW: Antibody-mediated neutralization in vivo of infectious papillomaviruses, J Virol 1990;64:3151-3156.
70. Christensen ND, Kimbauer R, Schiller JT, Ghim SJ, Schlegel R, Jenson AB, Kreider JW: Human papillomavirus types 6 and 11 have antigcnically distinct strongly immunogenic conformationally dependent neutralizing epitopes, Virology 1994;205:329-335.
71. Christensen ND, Kreider JW, Cladel NM, Patrick SD, Welsh PA: Monoclonal antibody mediated neutralization of infectious human papillomavirus type 11, J Virol 1990:64:5678- 5681.
72. Roden RB, Weissinger EM, Henderson DW, Booy F, Kimbauer R, Mushinski JF, Lowy DR, Schiller JT: Neutralization of bovine papillomavirus by antibodies to LI and L2 capsid proteins, J Virol 1994:68:7570-7574.
73. Carter JJ, Hagensee M, Taflin MC, Kuang Lee S, Koutsky LA, Galloway DA: HPV-1 capsids expressed in vitro detect human serum antibodies associated with foot warts, Virology-1993; 195:456-462.
74. Rose RC, Reichman RC, Bonnez W: Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera, J Gen Virol 1994:75: 2075-2079.
75. Heim K, Christensen N, Hoepll R, Wartusch B, Pinzger G, Zeimct A, Baumgartner P, Kreider J, Dapunt O: Serum IgG, IgM, and IgA reactivity to human papillomavirus tvpe-11 and type-6 virus-like particles in different gynecologic patient groups, J Infect Dis 1995:172: 395-402.
76. Carter J, Wipf G, Hagensee M, McKnight B, Habel L, Lee S, Kuypcrs J, Kiviat N, Dating J, Koutsky L, Watts D, Holmes K, Galloway D: Use of human papillomavirus lype-6 capsids to detect antibodies in people with genital warts, J Infect Dis 1995:172:11-18.
77. Favre M, Breitburd F, Croissant O, Orth G: Hemagglutinating activity of bovine papillomavirus, Virology 1974;60:572-578.
78. Roden R, Hubbert N, Kimbauer R, Breitburd F, Lowy D, Schiller J: Papillomavirus LI capsids agglutinate mouse erythrocytes through a proteinaceous receptor, J Virol 1995:69:5147- 5151.
79. Bell JA, Sundberg JP, Ghim SJ, Newsome J, Jenson AB, Schlegel R: A formalin-inactivated vaccine protects against mucosal papillomavirus infection: A canine model, Pathobiology 1994;62:194-198.
80. Breitburd F, Kirnbauer R, Hubbert NL, Non-ncnmacher B, Trin Dinh Desmarquet C, Orth G, Schiller JT, Lowy DR: Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection, J Virol 1995:69:3959-3963.
81. Muñoz N, Crawford L, Coursaget P: HPV vaccines and their potential use in the prevention and treatment of cervical neoplasia, Papillomavirus Rep 1995:6:54-55.
82. Kimbaucr R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, McGarvie GM, Schiller JT, Lowy DR, Campo MS: Virus-like particles ofbovine papillomavirus type 4 in prophylactic and therapeutic immunization, Virology 1996:219:37-44.